Reply to: 'Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered'

Authors :: Vincent Mallet
Kilian Bock
Mourad Dellagi
Marion Tano
Virginie Siorat
Nathanaël Beeker
Pascal Paubel
Paul Doumbe Mandengue
Nicolas Dufour
Torsten Voigtländer
Jean-Damien Ricard
Pierre Isnard
Vincent Frochot
Emmanuel Letavernier
Lucile Moga
Amandine Landrieux
Pierre-Emmanuel Rautou
Nathalie Pons-Kerjean
Anaïs Vallet-Pichard
Clémence Hollande
Hélène Fontaine
Laurent Chouchana
Coralie Gernez
Carole Burger
Anne Scemla
Christian de Tymowski
François Depret
Emmanuel Dudoignon
Lionel Lamhaut
Rémi Flicoteau
Géraldine Rousseau
Jean-Paul Duong Van Huyen
Jean-Michel Correas
Heiner Wedemeyer
Stanislas Pol
Source :: Journal of Hepatology. 75:990-992
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: medicine.medical_specialty
2019-20 coronavirus outbreak
Hepatology
Coronavirus disease 2019 (COVID-19)
medicine.diagnostic_test
business.industry
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
medicine.disease
Gastroenterology
Cholestasis
Internal medicine
medicine
Ketamine
Bile Duct Diseases
Liver function tests
business
medicine.drug

Full Text Access

Tools